In:
Hepatology, Ovid Technologies (Wolters Kluwer Health), Vol. 65, No. 3 ( 2017-03), p. 999-1014
Kurzfassung:
Prostaglandin E 2 (PGE 2 ) is an important lipid mediator of inflammation. However, whether and how PGE 2 regulates hepatic cholesterol metabolism remains unknown. We found that expression of the PGE 2 receptor, E prostanoid receptor 3 (EP3) expression is remarkably increased in hepatocytes in response to hyperlipidemic stress. Hepatocyte‐specific deletion of EP3 receptor ( EP3 hep–/– ) results in hypercholesterolemia and augments diet‐induced atherosclerosis in low‐density lipoprotein receptor knockout ( Ldlr –/– ) mice. Cholesterol 7α‐hydroxylase (CYP7A1) is down‐regulated in livers of EP3hep–/–Ldlr−/− mice, leading to suppressed hepatic bile acid (BA) biosynthesis. Mechanistically, hepatic‐EP3 deficiency suppresses CYP7A1 expression by elevating protein kinase A (PKA)‐dependent Ser143 phosphorylation of hepatocyte nuclear receptor 4α (HNF4α). Disruption of the PKA‐HNF4α interaction and BA sequestration rescue impaired BA excretion and ameliorated atherosclerosis in EP3hep–/–Ldlr−/− mice. Conclusion : Our results demonstrated an unexpected role of proinflammatory mediator PGE 2 in improving hepatic cholesterol metabolism through activation of the EP3‐mediated PKA/HNF4α/CYP7A1 pathway, indicating that inhibition of this pathway may be a novel therapeutic strategy for dyslipidemia and atherosclerosis. (H epatology 2017;65:999‐1014)
Materialart:
Online-Ressource
ISSN:
0270-9139
,
1527-3350
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2017
ZDB Id:
1472120-X
